Display options
Cite
Khan TZ, Pottle A, Pennell DJ, et al. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014;2014(1):3-12doi: 10.5339/gcsp.2014.3.
Khan, T. Z., Pottle, A., Pennell, D. J., & Barbir, M. S. (2014). The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Global cardiology science & practice, 2014(1), 3-12. https://doi.org/10.5339/gcsp.2014.3
Khan, Tina Z, et al. "The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina." Global cardiology science & practice vol. 2014,1 (2014): 3-12. doi: https://doi.org/10.5339/gcsp.2014.3
Khan TZ, Pottle A, Pennell DJ, Barbir MS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014 Jan 29;2014(1):3-12. doi: 10.5339/gcsp.2014.3. eCollection 2014. PMID: 25054114; PMCID: PMC4104372.
Copy Download .nbib Format: NLM
Share it on

Glob Cardiol Sci Pract. 2014 Jan 29;2014(1):3-12. doi: 10.5339/gcsp.2014.3. eCollection 2014.

The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.

Global cardiology science & practice

Tina Z Khan, Alison Pottle, Dudley J Pennell, Mahmoud S Barbir

Affiliations

  1. Royal Brompton and Harefield Hospital NHS Foundation Trust, Hill End Road, London, UB9 6JH, United Kingdom.

PMID: 25054114 PMCID: PMC4104372 DOI: 10.5339/gcsp.2014.3

Abstract

It is increasingly recognised that lipoprotein(a) [Lp(a)], an inherited, genetically-determined form of LDL-cholesterol, is an independent cardiovascular risk factor and predictor of adverse cardiovascular outcomes. Lp(a) is felt to increase cardiovascular risk via its pro-thrombotic effect and by enhancing intimal lipoprotein deposition. Lipoprotein apheresis is currently the most effective treatment for raised Lp(a). There is a growing body of evidence suggesting that aggressively lowering raised Lp(a) may improve cardiovascular and clinical outcomes, although much more research is required in this field. Angina which is refractory to conventional medical therapy and revascularisation, is extremely challenging to manage. Treatment options for such patients remain very limited. We describe the case of a patient with refractory angina and raised lipoprotein(a) in whom aggressive reduction of Lp(a) with lipoprotein apheresis successfully ameliorated the progression of coronary stenosis and provided effective and durable relief of angina symptoms. In our centre, we are currently conducting a prospective, randomised controlled cross-over study of patients with refractory angina and raised Lp(a), randomised to undergoing lipoprotein apheresis or 'sham' apheresis with assessment of myocardial perfusion, carotid atherosclerosis, endothelial vascular function, thrombogenesis, oxidised phospholipids and their antibodies, exercise capacity, angina symptoms and quality of life at the beginning and end of treatment.

Keywords: Ischaemic heart disease; Lipoprotein Apheresis; Lipoprotein(a); Refractory angina

References

  1. Lancet. 2000 Jul 22;356(9226):279-84 - PubMed
  2. Dis Mon. 2006 Jan;52(1):5-50 - PubMed
  3. J Am Coll Cardiol. 1999 Jun;33(7):1833-40 - PubMed
  4. J Lipid Res. 2008 Oct;49(10):2230-9 - PubMed
  5. JAMA. 2009 Jul 22;302(4):412-23 - PubMed
  6. Ther Apher Dial. 2009 Apr;13(2):129-37 - PubMed
  7. Eur Heart J. 2013 May;34(17):1279-91 - PubMed
  8. Am J Med Sci. 1966 Sep;252(3):289-95 - PubMed
  9. Heart. 2004 Feb;90(2):225-30 - PubMed
  10. Blood. 1999 Sep 15;94(6):2007-19 - PubMed
  11. Br Heart J. 1994 May;71(5):406-7 - PubMed
  12. JAMA. 1995 Dec 13;274(22):1771-4 - PubMed
  13. N Engl J Med. 2009 Dec 24;361(26):2518-28 - PubMed
  14. J Am Coll Cardiol. 2011 Apr 12;57(15):1611-21 - PubMed
  15. J Am Coll Cardiol. 1999 Nov 15;34(6):1663-70 - PubMed
  16. Circulation. 2008 Jan 15;117(2):176-84 - PubMed
  17. Transfus Apher Sci. 2010 Feb;42(1):21-6 - PubMed
  18. Ther Apher. 1997 Aug;1(3):242-8 - PubMed
  19. Ther Apher. 2002 Apr;6(2):130-5 - PubMed
  20. Atherosclerosis. 1999 Apr;143(2):229-43 - PubMed
  21. Eur Heart J. 2010 Dec;31(23):2844-53 - PubMed
  22. Atherosclerosis. 1998 Jul;139(1):173-8 - PubMed
  23. Arterioscler Thromb. 1993 Aug;13(8):1139-58 - PubMed
  24. Atheroscler Suppl. 2013 Jan;14(1):93-9 - PubMed
  25. Eur Heart J. 2002 Mar;23(5):355-70 - PubMed
  26. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1162-7 - PubMed
  27. Transfus Apher Sci. 2009 Aug;41(1):61-5 - PubMed
  28. Curr Opin Lipidol. 2010 Dec;21(6):492-8 - PubMed
  29. Am J Epidemiol. 1992 Aug 15;136(4):441-9 - PubMed
  30. J Clin Apher. 2005 Dec;20(4):252-5 - PubMed
  31. Arterioscler Thromb. 1991 May-Jun;11(3):629-38 - PubMed
  32. Blood. 2001 Nov 15;98(10):2980-7 - PubMed
  33. Acta Pathol Microbiol Scand. 1963;59:369-82 - PubMed
  34. Pharmacol Ther. 2010 Jun;126(3):314-45 - PubMed
  35. Circulation. 2000 Sep 5;102(10):1082-5 - PubMed
  36. Diabetes Obes Metab. 2002 Jul;4(4):255-61 - PubMed
  37. Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):229-39 - PubMed
  38. Circulation. 2013 Aug 27;128(9):962-9 - PubMed
  39. J Clin Lipidol. 2012 Mar-Apr;6(2):192-4 - PubMed
  40. Circulation. 2001 Sep 4;104(10):1108-13 - PubMed
  41. J Am Coll Cardiol. 2002 Mar 20;39(6):923-34 - PubMed
  42. J Am Coll Cardiol. 2010 Sep 14;56(12):946-55 - PubMed
  43. Arch Intern Med. 2008 Mar 24;168(6):598-608 - PubMed
  44. Clin J Pain. 1998 Dec;14(4):315-9 - PubMed
  45. Eur J Clin Invest. 1994 Jul;24(7):444-53 - PubMed

Publication Types